share_log

復星醫藥：海外監管公告 - 關於控股子公司獲藥品註冊申請受理的公告

FOSUN PHARMA: Overseas Regulatory Announcement - Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

HKEX ·  Nov 4 17:57

Summary by Futu AI

上海復星醫藥（集團）股份有限公司宣布，其控股子公司重慶藥友製藥有限責任公司的左氧氟沙星注射液（新藥1）和吉斯美（武漢）製藥有限公司的阿糖胞苷注射液（新藥2）的藥品註冊申請已獲國家藥品監督管理局受理。新藥1和新藥2均為復星醫藥自主研發的化學藥品，分別用於治療多種感染和白血病。截至2024年9月，對這兩種新藥的研發投入分別約為人民幣133萬元和257萬元。根據IQVIA最新數據，相關藥品在中國內地的銷售額顯著。公司提醒投資者，新藥商業化生產前尚需藥品註冊批准，且藥品銷售存在不確定性，敬請注意投資風險。
上海復星醫藥（集團）股份有限公司宣布，其控股子公司重慶藥友製藥有限責任公司的左氧氟沙星注射液（新藥1）和吉斯美（武漢）製藥有限公司的阿糖胞苷注射液（新藥2）的藥品註冊申請已獲國家藥品監督管理局受理。新藥1和新藥2均為復星醫藥自主研發的化學藥品，分別用於治療多種感染和白血病。截至2024年9月，對這兩種新藥的研發投入分別約為人民幣133萬元和257萬元。根據IQVIA最新數據，相關藥品在中國內地的銷售額顯著。公司提醒投資者，新藥商業化生產前尚需藥品註冊批准，且藥品銷售存在不確定性，敬請注意投資風險。
Shanghai Fosun Pharma (Group) Co., Ltd. announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd.'s Levofloxacin Injection (New Drug 1) and Gedesmei (Wuhan) Pharmaceutical Co., Ltd.'s Azacitidine Injection (New Drug 2) pharmaceutical registration applications have been accepted by the National Medical Products Administration. New Drug 1 and New Drug 2 are both chemical drugs independently developed by Fosun Pharma, used respectively for treating various infections and leukemia. As of September 2024, the research and development investment for these two new drugs is approximately RMB 1.33 million and 2.57 million yuan, respectively. According to the latest IQVIA data, the sales of related drugs in mainland China are significant. The company reminds investors that before the commercial production of new drugs, drug registration approval is still required, and there are uncertainties in drug sales. Please be cautious of investment risks.
Shanghai Fosun Pharma (Group) Co., Ltd. announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd.'s Levofloxacin Injection (New Drug 1) and Gedesmei (Wuhan) Pharmaceutical Co., Ltd.'s Azacitidine Injection (New Drug 2) pharmaceutical registration applications have been accepted by the National Medical Products Administration. New Drug 1 and New Drug 2 are both chemical drugs independently developed by Fosun Pharma, used respectively for treating various infections and leukemia. As of September 2024, the research and development investment for these two new drugs is approximately RMB 1.33 million and 2.57 million yuan, respectively. According to the latest IQVIA data, the sales of related drugs in mainland China are significant. The company reminds investors that before the commercial production of new drugs, drug registration approval is still required, and there are uncertainties in drug sales. Please be cautious of investment risks.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated